We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Microarray-Based COVID-19 Test Analyzes Sample in Triplicate for Each Patient Swab Within Each Array For 100% Specificity

By LabMedica International staff writers
Posted on 22 Jul 2021
A low-cost, high-throughput microarray-based test ensures 100% specificity by analyzing the sample in triplicate for each patient swab within each array, as compared to just once by COVID-19 tests that are currently approved.

PathogenDx, Inc. (Scottsdale, AZ, USA) has received the CE-IVD Mark for the sale and distribution of its patented DetectX-Rv Microarray Assay for COVID-19 testing across Europe. PathogenDx's DetectX-Rv microarray utilizes nasopharyngeal swabs and nasal aspirate or fluid to detect SARS-CoV2 within three hours after RNA extraction, and has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA). Its multiplex system also has the capability of pooled sample testing for the detection of SARS-CoV2 in multiple samples at one time, dramatically increasing COVID-19 testing throughput.

Image: DetectX-Rv Microarray Assay (Photo courtesy of PathogenDx, Inc.)
Image: DetectX-Rv Microarray Assay (Photo courtesy of PathogenDx, Inc.)

DetectX-Rv delivers superior accuracy based on its proprietary technology of analyzing dozens of probes in COVID-19 regions of the viral genome, delivering a Limit of Detection of 1,000 copies/mL. The test also ensures 100% specificity by analyzing the sample in triplicate for each patient swab within each array, not just once as conducted in currently approved COVID-19 tests.

"Receiving the CE-IVD Mark for our DetectX-Rv test is a massive milestone for our company and will not only help detect COVID-19 in Europe as the pandemic sweeps on, but with the company's follow-on Detect-Cv Clade variant test helps identify the Variant of Concern and/or Variant of Interest from any positive result processed either from DetectX-Rv or any other molecular platform," said Milan Patel, Co-founder and CEO of PathogenDx. "Although we are in the second year of the pandemic and vaccine distribution has greatly improved, COVID-19 and its variants persist in our global community. The virus will continue to mutate and we need to be able to identify if an infected patient has a particular variant in order to provide the most effective clinical and therapeutic treatment. Global distribution of diagnostic tests like our DetectX-Rv test is crucial in helping limit the spread of COVID-19 and its variants."

Related Links:
PathogenDx, Inc.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Latest COVID-19 News

New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases

Long COVID Etiologies Found in Acute Infection Blood Samples

Novel Device Detects COVID-19 Antibodies in Five Minutes